Gilead Sciences: Pipeline, Products, Performance, Potential

Date: February 22, 2010
Pages: 72
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G837F6B129DEN

Download PDF Leaflet

Gilead Sciences: Pipeline, Products, Performance, Potential
Gilead’s HIV product portfolio remains its strongest asset, generating 81.2 per cent of total company sales in 2008. Atripla and Truvada are expected have combined sales approaching US$5 billion by 2013, and will remain the main growth drivers for the company in the foreseeable future. Beyond the HIV portfolio, AmBisome and Hepsera remain important products for Gilead and are forecast to contribute strongly to sales. In addition, the acquisition of Myogen has provided Gilead with exclusive rights to Letairis, which was launched for pulmonary hypertension in the US and Europe in 2007 and 2008 respectively. Initial sales of Letairis have been promising, further validating Gilead's move into non-virology fields. Viread is the only major product forecast to experience declining sales, and this can be attributed to cannibalisation effects caused by the success of Atripla and Truvada. Seeking to maximise the value of Viread, Gilead is looking to launch the product for the treatment of hepatitis B. The acquisition of Raylo Chemicals and Nycomed's Irish subsidiary provides Gilead with the manufacturing facilities and infrastructure to meet growing demand for all its products, especially the new HIV combination drugs.

It would seem Gilead’s gamble seems justifiable, with the acquisitions providing the company with the tools for long-term growth. One remaining significant threat to this growth is Gilead’s reliance on its key agreements with other pharmaceutical companies. In 2007, royalty and contract revenue accounted for 11.8 per cent of company revenue, and much of this can be attributed to improved sales of Tamiflu by Roche. This contribution has been reduced to 4.7 per cent of company revenue in fiscal 2008 due to lower demand for Tamiflu. Further declines are anticipated. Furthermore. Atripla has already been cited as a key product for future growth, however, its success will depend on the working relationship between Bristol-Myers Squibb, Merck & Co and Gilead, who are working in a three-way joint venture centred on the marketing of this product.

This new strategic analysis report Gilead Sciences: Pipeline • Products • Performance • Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.


Key product analysis and forecasting

  Atripla (emtricitabine+tenofovir disoproxil fumarate+efavirenz)
  Truvada (emtricitabine+tenofovir disoproxil fumarate)
  Viread (tenofovir disoproxil fumarate)
  Hepsera (adefovir dipivoxil)


A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Subsidiaries and joint ventures
Skip to top

Biogen Idec: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 86 pages
Chugai: Pipeline, Products, Performance, Potential US$ 1,040.00 Oct, 2009 · 80 pages
Otsuka: Pipeline, Products, Performance, Potential US$ 1,040.00 Apr, 2008 · 80 pages

Ask Your Question

Gilead Sciences: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: